NCT03052530已完成不适用
Sapphire II PRO - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Procedural Success of the Sapphire II PRO 1.0 and 1.25 mm PTCA Dilatation Catheters.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- OrbusNeich
- 入组人数
- 61
- 试验地点
- 8
- 主要终点
- Number of Participants With Device Procedural Success
研究概览
简要总结
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during percutaneous coronary intervention.
Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters 1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria:
- •Subject is ≥ 18 years of age.
- •Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
- •Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.
- •Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.
- •Angiographic Inclusion Criteria
- •Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.
- •A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
- •Target and non-target lesions must be located in different coronary arteries or bypass grafts.
- •Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO)
- •Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.
排除标准
- •Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
- •Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.
- •Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- •Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- •A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
- •Cerebrovascular accident (CVA) within the past 6 months.
- •Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- •Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary)
- •Angiographic Exclusion Criteria
- •More than two lesions requiring treatment.
- •Unprotected left main coronary artery disease.(Greater than 50% diameter stenosis)
- •Coronary artery spasm of the target vessel in the absence of a significant stenosis.
- •Target lesion with angiographic presence of probable or definite thrombus.
- •Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.
- •Non-target lesion to be treated during the index procedure meets any of the following criteria:
- •Located within a bypass graft (venous or arterial)
- •Left main location
- •Chronic total occlusion
- •Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- •Treatment not deemed a clinical angiographic success
结局指标
主要结局
Number of Participants With Device Procedural Success
时间窗: Peri-procedural (at Day 0)
Device procedural success consisting of the following: * Successful delivery, inflation, deflation and withdrawal of the study balloon * No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon * Final TIMI flow grade of 3 at the conclusion of the PCI procedure
次要结局
- Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)(Endpoints will be measured through hospital discharge (expected to be within 24 hours))
- Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel(Endpoint will be measured through hospital discharge (expected to be within 24 hours))
- Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)(Endpoint will be measured through hospital discharge (expected to be within 24 hours))
研究者
研究点 (8)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRelapsed/Refractory Large Granular T Lymphocytic LeukemiaNCT06224257Institute of Hematology & Blood Diseases Hospital, China41
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261
招募中
2 期
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)Gastric CancerNCT05536102Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine38
已完成
2 期
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaMultiple MyelomaNCT03601078Celgene312
已完成
2 期
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal CarcinomaFAPPDAC - Pancreatic Ductal AdenocarcinomaNCT05262855SOFIE63